score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical		Preclinical	Copy Number	AURKA	Amplification				0.0	0.0		Putatively Actionable	Danusertib	Aurora kinase inhibition	Targeted therapy	Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).	Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.	https://doi.org/10.1158/2159-8290.CD-11-0130								Putatively Actionable	0.0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153	0				AURKA Amplification		KIRP-4A-A93X	TCGA-4A-A93X-01	
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R725*	0.593	172.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	0.0	0.0	0.0	PBRM1 p.R725* (Nonsense)		KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Investigate Actionability	Clinical evidence			Somatic Variant	TSC1	Frameshift	p.T26fs	0.3889	36.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344													0	0.0	0.0	0.0	TSC1 p.T26fs (Frameshift)		KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.I878S	0.0328	183.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0	0.0	0.0	0.0	MET p.I878S (Missense)	0.0	KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q822*	0.9167	36.0	0.0	0.0																Investigate Actionability	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	2.0	1.0	0.0	STAG2 p.Q822* (Nonsense)		KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						KIRP-4A-A93X		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.H186N	0.8734	79.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0	0.0	0.0	0.0	CHEK2 p.H186N (Missense)	0.0	KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Splice Site		0.32	50.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951													0	0.0	0.0	0.0	PBRM1  (Splice Site)		KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E66D	0.38299999999999995	47.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616						0	0.0	0.0	0.0	NFE2L2 p.E66D (Missense)		KIRP-4A-A93X	KIRP-4A-A93X-TP	KIRP-4A-A93X-NB
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.PPA66del (Deletion)		KIRP-4A-A93X		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.206																									0				COSMIC Signature (version 2) 1 (21%)		KIRP-4A-A93X		
Biologically Relevant				Mutational Signature	COSMIC Signature 9	version 2	0.253																									0				COSMIC Signature (version 2) 9 (25%)		KIRP-4A-A93X		
